« Return to News | R&D Trends

Phase Forward Revenue Jumps 30%

Wednesday, July 30, 2008 09:07 AM

Waltham, Mass.-based Phase Forward, a provider of data management solutions for clinical trials and drug safety, reported after the bell Monday a 30% jump in second quarter revenues to $40.9 million from $31.5 million in the second quarter of 2007.

Bob Weiler, CEO and president of Phase Forward, said, "During the quarter, we signed noteworthy deals with both new and existing customers across the range of our target markets. We are particularly pleased with the continued success of our CRO [contract research organization] Advantage Program during the quarter, as evidenced by winning new CRO customers and deepening our relationships with a number of existing strategic CRO partners."

For the second quarter of 2008, income from operations was $4.2 million, compared with $3.2 million in the second quarter of 2007. For the second quarter of 2008, income from operations was $6.4 million, a 42% rise from the prior year period and an operating margin of 15.7%.

Phase Forward's shares closed down 1.6% at $18.37 on Tuesday.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.